Malignancies in women with HIV infection

Women's Health

Volumn 4, Issue 4, 2008, Pages 357-368

  Krishnan, Amrita ^a   Levine, Alexandra M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

AIDS related malignancy; HIV; Human papillomavirus

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN C; PREDNISONE; TRICHLOROACETIC ACID; VINCRISTINE; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACQUIRED IMMUNE DEFICIENCY SYNDROME RELATED LYMPHOMA; ANUS CANCER; ANUS DYSPLASIA; ANUS SURGERY; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONDYLOMA; CONDYLOMA ACUMINATUM; CONTINUOUS INFUSION; CRYOTHERAPY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG MEGADOSE; DYSPLASIA; FEMALE; HEAD AND NECK CANCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; LOW LEVEL LASER THERAPY; LYMPHOMA; METASTASIS; MOUTH CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PREVALENCE; REVIEW; RISK FACTOR; SQUAMOUS INTRAEPITHELIAL LESION; SURGICAL TECHNIQUE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERUS DISEASE; VACCINATION; VERRUCOUS CARCINOMA; VIRUS CARCINOGENESIS; VIRUS LIKE AGENT; WART VIRUS; WOMEN'S HEALTH;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; WOMEN'S HEALTH;

EID: 48749129698     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.4.357     Document Type: Review

References (74)

1. Shibata D, Weiss LM, Hernandez AM et al.: Espstein-Barr virus associated with non-Hodgkin lymphoma in patients with the human immunodeficiency virus. Blood 81, 2102-2109 (1993).
2. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20, 7874-7882 (2001).
3. Khan MJ, Castle PE, Lorincz AT et al.: The elevated 10 year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type specific HPV testing in clinical practice. J. Natl Cancer Inst. 97, 1072-1079 (2005).
4. Frisch M, Biggar R, Goedert J: Human papillomavirus associated cancers in patients with human Immunodeficiency virus infection and acquired immunodeficiency syndrome. J. Natl. Cancer Inst. 92, 1500-1510 (2000).
5. Frisch M, Biggar R, Engels E et al.: Association of cancer with AIDS related immunosuppression in adults. JAMA 285, 1736-1744 2001).
6. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F: Carcinogenicity of human papillomaviruses. Lancet Oncol. 6, 204 (2005).
7. Palefsky JM, Hollv F.A. Ralston ML et al.: Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J. Infect. Dis. 183, 383 (2001).
8. Chiao E, Krown SE, Stier EA et al.: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J. AIDS 40, 451-455 (2005).
9. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J. Clin. Oncol. 24, 2606-2611 (2006).
10. Licitra L, Perrone F, Bossi P et al.: High risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin. Oncol. 24, 5630-5636 (2006).
11. Mork J, Lie AK, Glattre E et al.: Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125-1131 (2001).
12. Ateenyi-Agaba C: Conjunctival squamus-cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet 345, 695-696 (1995).
13. Palefsky JM, Minkoff H, Kalish L et al.: Cervicovaginal human papillomavirus infection in HIV positive and high risk HIV negative women. J Natl Cancer Inst. 91, 226-236 (1999).
14. Strickler HD, Burk RD, Fazzari M et al.: Natural history and possible reactivation of human papillomavirus in human immunodfeficiency virus positive women. J Natl Cancer Inst. 97, 577-586 (2005).
15. Vermund S, Kelley K, Klein R et al.: High risk of human papillomavirus and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am. J. Obstet. Gynecol. 165, 392-400 (1991).
16. Wallin KL, Wiklund F, Angstrom T et al.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl J. Med. 341, 1633-1638 (1999).
17. Sun XW, Kuhn L, Ellerbrock TV et al.: Human papillomavirus infection in women infected with the human immunodeficiency virus. N. Engl. J. Med. 337, 1343-1349 (1997).
18. Harris T, Burk RD, Palefsky JM et al.: incidence of cervical squamous intraepithetial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 293, 1471-1476 (2005).
19. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1), S16-S24 (2005).
20. Quinn TC, Glasser RO et al.: Human Immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N. Engl. J. Med. 318, 197-203 (1988).
21. Clifford GM, Goncalves MA, Franceschi S: Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20, 2337-2344 (2006).
22. Koutsky LA, Galloway DA, Holmes KK: Epipidemiology of genital human papillomavirus infection. Epidemiol. Rev. 10, 122-163 (1988).
23. Vernon SD, Hart CE, Reeves WC. Icenogle FP: The HIV-1 tat protein enhances E2 dependent human papillomavirus 16 transcription. Virus Res. 27, 133-145 (1993).
24. Six C, Heard I, Bergeron C et al.: Comparative prevalence, incidence and short term prognosis of cervical squamous intraepithelial lesions amongst HIV positive and HIV negative women. AIDS 12, 1047-1056 (1997).
25. Mandelblatt JS, Kanetsky P, Eggert L, Gold K: Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol. Biomarkers Prev. 8, 97-106 (1999).
26. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 324, 7-27 (2004).
27. Solomon D, Davey D, Kurman R et al.: The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287, 2114-2119 (2002).
28. Moscicki AB, Shiboski S, Hills NK et al.: Regression of low grade squamous intra depithelial lesions in young women. Lancet 364, 1678-1683 (2004).
29. Cox JT, Schiffman M, Solomon D: Prospective follow up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervivical intraepithelial neoplasia grade 1 or negative colposcopy and direted biopsy. Am. J. Obstet. Gynecol. 188, 1406-1412 (2003).
30. Hawes S, Critchlow C, Niang F et al.: Increased risk of high grade cervical squamous intraepithelial lesions and invasive cervical cancer among african women with human immunodeficiency virus type 1 and 2 infections. J. Infect. Dis. 188, 555-563 (2003).
31. Ellerbrock T, Chiasson MA, Bush T et al.: Incidence of cervical squamous intraepithelial Lesions in HIV infected women. JAMA 283, 1031-1037 (2000).
32. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287, 2120-2129 (2002).
33. Cox JT: Management of cervical intraepithelial neoplasia. Lancet 353, 857-859 (1999).
34. Holcomb K, Matthews RP, Chapman JF. et al.: The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasta in HIV seropositive women. Gynecol. Oncol. 74, 428-431 (1996).
35. Fruchter RG, Maiman M, Sediis A et al.: Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet. Gynecol. 87, 338-344 (1996).
36. Mamian M, Fruchter RG, Clark M et al.: Cervical cancer as an AIDS defining illness. Obstet. Gynecol. 89, 76-80 (1997).
37. Maiman M, Fruchter RG, Guy L et al.: HIV infection and invasive cervical carcinoma. Cancer 71, 402-406 (1993).
38. Dorrucci M, Suligoi B, Serriano D et al.: Incidence of invasive cervical cancer in a cohort of HIV-seropositive women before and after the introduction of highly active antiretroviral therapy, J. AIDS 26, 377 (2001).
39. Maimam M: Cervical neoplasia in women with HIV infection. Oncology (Williston Park) 8(8), 83-94; discussion 89 (1994).
40. Cannistra S, Niloff J: Cancer of the uterine cervix. N. Engl. J. Med. 1030-1038 (1996).
41. Klevens RM, Fleming PL, Mays MA, Frey R: Characteristics of women with AIDS and invasive cervical cancer. Obstet. Gynecol. 88, 269-273 (1996).
42. Heard I, Tassie JM, Kazatchkine MD et al.: Highly active antiretroviral theraphy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 16, 1799 (2002).
43. Ahdieh-Grant L, Li R, Levine AM et al.: Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive Women. J. Natl Cancer Inst. 96, 1070-1076 (2004).
44. Sawaya GF, McConnell KJ, Kulasingam SL et al.: Risk of cervical cancer associated with extending the interval between cervical cancer screenings. N. Engl. J. Med. 349, 1501-1509 (2003).
45. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 370, 890-907 (2007).
46. Bulkmans J, Berkhof J, Rozendaal L et al.: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer; 5 year follow up of a randomized controlled implementation trial. Lancet 370, 1764-1776 (2007).
47. Ronco G, Segnan N: HPV testing for primary cervical cancer screening. Lancet 370, 1740-1742 (2007).
48. Schiffman M, Castle PE: The promise of global cervical cancer prevention. N. Engl. J. Med. 353(20), 2101-2104 (2005).
49. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. N. Engl. J. Med., 356, 1915-1927 (2007).
50. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356. 1928-1943 (2007).
51. Dunne EF, Unger ER, Sternberg M et al.: Prevalence of HPV infection among females in the United States. JAMA 297, 813-19 (2007).
52. Palefsky JM: Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus positive men and women. J. Natl Cancer Inst. 23, 15-20 (1998).
53. Palefsky JM, Holly EA, Ralston ML et al.: Effect of highly active antiretroviral therapy on the natural history of anal squamous epithelial lesions and human papillomarivrus infection. J. Acquir. Immune Defic. Syndr. 23, 422-428 (2001).
54. Grulich A, Van Leeuwen M et al.: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59-62 (2007).
55. Chang GJ, Berry JM, Jay N et al.: Surgical treatment of high grade and squamous intraepithelial lesions: a prospective study. Dis. Colon Rectum 45, 453-458 (2002).
56. Stier EA, Gladstone SE, Berry JM et al.: Infrared coagulator treatment of high gradeanal dysplasia in HIV infected individuals. J. Acquir. Immune Defic. Syndr. 47, 56-61 (2008).
57. Panther LA, Schlecht HP, Dezube BJ: Spectrum of HPV related dysplasia and carcinoma of the anus in HIV infected patients. AIDS Reader 15, 79-81 (2005).
58. Cleator S, Fife K, Nelson M et al.: Treatment of HIV-associated invasive anal cancer with combined chemoradiation. Eur. J. Cancer 36, 754-758 (2000).
59. Hoffman R, Welton ML, Klenecke B et al.: The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV positive patients with anal cancer. Int. J. Radiat. Oncol. Biol. Phys. 44, 127-131 (1999).
60. Gillison ML: Human papillomavirus virus associated head and neck cancer is a distinct epidemiologic, clinical and molecular entity Semin. Oncol. 31, 744-754 (2004).
61. Ledergerber B, Teleuti A et al.: Risk or HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV cohort study. Br. Med. J. 319, 23 (1999).
62. Mbulaiteye SM, Biggar RJ, Goedert JJ et al.: Immune deficiency and risk for malignancy among persons with AIDS. J. AIDS 32, 527-533 (2003).
63. Biggar RJ, Jaffe FS, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108, 3786-3791 (2006).
64. Besson C, Goubar A, Gabarre J et al.: Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98, 2339 (2001).
65. Levine AM, Seneviratne L, Espina BM et al.: Evolving characteristics of AIDS related lymphoma, Blood 96, 4084-4090 (2000).
66. Kaplan L, Abrams DI, Feigai E: Low dose versus standard dose MBACOD chemotherapy for HIV associated NHL. N. Engl. J. Med. 336, 1641-1648 (1997).
67. Ratner L, Lee J, Tang S. Redden D et al.: Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. 19, 2177-2178 (2001).
68. Little R, Pitaluga S, Graw N et al.: Highly effective treatment of acquired immunodeficiency NHI, with dose adjusted EPOCH: impact of antiviral therapy and suspension and tumor biology. Blood 101, 4653-4659 (2003).
69. Hoffman C, Wolf E, Fatkenheuer G et al.: Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 17, 1521-1529 (2003).
70. Krishnan A, Molina A, Zaia J et al.: Durable remissions with autologous stem cell transplant in HIV associated lymphoma. Blood 105, 874-878 (2005).
71. Levine AM: Hodgkin lymphoma: to the HAART of the matter. Blood 108, 3630 (2006).
72. Hentrich M, Maretta L, Chow KU et al.: Highly active antiretroviral therapy improves survival in HIV associated Hodgkin's disease: results of a multicenter study. Ann. Oncol. 17, 914-919 (2006).
73. Hurlye J, Franco S, Gomez-Fernandez C et al.: Breast cancer and human immunodeficiency virus: a report of 20 cases. Clin. Breast Cancer 2, 215-220 (2001).
74. Patel P, Hanson DI, Sullivan PS et al.: Incidence of types of cancer among HIV infected persons compared with the general population in the United States, 1992-2003. Ann. Intern. Med. 148, 728-726 (2008).